LEADING EUROPEAN UNIVERSITIES CHOOSE ELEKTA TO DELIVER ADVANCED 3D BRAIN MAPPING TOOL FOR RESEARCH

LEADING EUROPEAN UNIVERSITIES CHOOSE ELEKTA TO DELIVER ADVANCED 3D BRAIN MAPPING
TOOL FOR RESEARCH

Elekta Neuromag®, the world-leading equipment for non-invasive measurement of
brain activity using magnetoencephalography (MEG) technology has been ordered by
the Moscow Municipal University of Psychology and Education (Moscow, Russia) and
the University of Trento (Trento, Italy).

MEG is a powerful tool for studying normal brain function and brain disorders.
Elekta Neuromag is the world's most advanced and most used MEG system, providing
real-time mapping of brain activity by non-invasively measuring the magnetic
fields produced by the brain. Electrical activity in neurons in the brain
produce magnetic fields that pass through brain tissue and the skull, which can
then be recorded outside the head using Elekta Neuromag.

The first whole-head MEG in Russia, neuroscientists and those in related fields
at the Moscow Municipal University of Psychology and Education, plan to use
Elekta Neuromag for clinically oriented research applications, such as autism in
children. The University also plans to employ MEG technology for cognitive
neuroscience and neuropsychology research such as the study of human emotion and
brain abnormalities. 

“We are extremely excited about our upcoming installation,” says Professor
Tatiana Stroganova, the Head of the Developmental Psychophysiology Department.
“We plan to use the MEG extensively to study temporal dynamics of cortical
networks underlying normal and aberrant brain organization of perception,
attention and emotion.” 

Dedicated to brain and cognitive neuroscience research, a large group of
researchers at the University of Trento's Center of Mind/Brain Sciences (CIMeC)
plan to use Elekta Neuromag to explore various fields of neuroscience such as
sensory processing, attention and action control, language, formation of
concepts and cognitive development.

The University of Trento has recruited physicians from Italy and elsewhere in
Europe, including Dr. Christoph Braun, former head of the MEG-Center at the
Eberhard Karls University Tübingen (Tübingen, Germany).

“The addition of Elekta Neuromag will complement already established methods
such as 4T functional magnetic resonance tomography (fMRT), transcranial
magnetic stimulation (TMS) as well as multi-channel EEG - thus contributing to
the advancement of our understanding of the brain,” says Dr. Braun.

The University's MEG-lab is situated in the Italian countryside. “Not only is
our MEG-lab optimally located for brain activity measurement, but patients also
have an opportunity to enjoy a beautiful view of the Alps,” continues Braun.

“The acquisition of Elekta Neuromag by two prominent European Universities is a
major opportunity for Elekta to work with Europe's top scientists in this
field,” says Stephen Otto, Chairman of Elekta's Neuromag Business. “We look
forward to working with the Moscow Municipal University of Psychology and
Education and the University of Trento and hope the MEG systems will provide
valuable information to each of their respective programs.”


For further information, please contact:

Michelle Lee, Media Contact, Elekta Inc. 
Tel: +1 770 670 2447, e-mail: michelle.lee@elekta.com

Lena Schattauer, Investor Relations, Elekta AB
Tel: +46 70 595 51 00, e-mail: lena.schattauer@elekta.com   


About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.